NLRP3 and breast carcinoma: Recently, Yao et al. found that in triple-negative MDA-MB-231 breast cancer cells, berberine was able to inhibit the pathway of NLRP3 inflammasome, by reducing the mRNA expression of NLRP3, caspase-1 and IL-1β and decreasing the protein expression of P2X7, NLRP3, pro-caspase-1 and ASC in a dose-dependent manner [135].